Education
About Us
Working with TipRanks
Follow Us
eFFECTOR Therapeutics (EFTR)
OTHER OTC:EFTR
RESEARCH TOOLSreports
EFTR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $0.06
Previous CloseN/A
Volume10.00
Average Volume (3M)38.30K
Market Cap
$941.00
Enterprise Value$4.74M
Total Cash (Recent Filing)$25.38M
Total Debt (Recent Filing)$20.25M
Price to Earnings (P/E)―
Beta-56.58
Next Earnings
May 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.31
Shares Outstanding4,704,409
10 Day Avg. Volume22,048
30 Day Avg. Volume38,305
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap5.04K
Enterprise Value/Revenue14.63
Enterprise Value/Gross Profit92.96
Enterprise Value/Ebitda-0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
eFFECTOR Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
4.62% Insiders
<0.01% Mutual Funds
1.31% Other Institutional Investors
98.69% Public Companies and
Individual Investors
EFTR FAQ
What was eFFECTOR Therapeutics’s price range in the past 12 months?
eFFECTOR Therapeutics lowest stock price was $0.03 and its highest was $0.06 in the past 12 months.
What is eFFECTOR Therapeutics’s market cap?
eFFECTOR Therapeutics’s market cap is $941.00.
When is eFFECTOR Therapeutics’s upcoming earnings report date?
eFFECTOR Therapeutics’s upcoming earnings report date is May 13, 2025 which is 70 days ago.
How were eFFECTOR Therapeutics’s earnings last quarter?
Currently, no data Available
Is eFFECTOR Therapeutics overvalued?
According to Wall Street analysts eFFECTOR Therapeutics’s price is currently Overvalued.
Does eFFECTOR Therapeutics pay dividends?
eFFECTOR Therapeutics does not currently pay dividends.
What is eFFECTOR Therapeutics’s EPS estimate?
eFFECTOR Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does eFFECTOR Therapeutics have?
eFFECTOR Therapeutics has 4,704,409 shares outstanding.
What happened to eFFECTOR Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of eFFECTOR Therapeutics?
Currently, no hedge funds are holding shares in EFTR
Company Description
eFFECTOR Therapeutics
eFFECTOR Therapeutics, Inc. (EFTR) is a biopharmaceutical company focused on the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company operates within the biotechnology sector, with a particular emphasis on harnessing the body's translational control mechanisms to modulate protein production associated with cancerous growth. Its core services revolve around the discovery, development, and commercialization of innovative therapies aimed at improving the lives of patients afflicted with various cancer types.
Fate Therapeutics
―
Karyopharm Therapeutics
―
Arcutis Biotherapeutics
―
Immatics
―
Foghorn Therapeutics
―